PE20142329A1 - Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona - Google Patents
Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-onaInfo
- Publication number
- PE20142329A1 PE20142329A1 PE2014000758A PE2014000758A PE20142329A1 PE 20142329 A1 PE20142329 A1 PE 20142329A1 PE 2014000758 A PE2014000758 A PE 2014000758A PE 2014000758 A PE2014000758 A PE 2014000758A PE 20142329 A1 PE20142329 A1 PE 20142329A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- etoxy
- diazaspiro
- decan
- ona
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UNA FORMA (I) CRISTALINA ANHIDRA DE LA SAL DE HIDROCLORURO DE (5S,8S)-8-[{(1R)-1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-DIAZASPIRO[4.5]DECAN-2-ONA (FORMULA I) QUE PRESENTA UN PATRON DE DIFRACCION DE POLVO DE RAYOS X QUE TIENE PICOS PRESENTES EN LOS ANGULOS DE DIFRACCION EN 2 THETA DE: 12,9 (S), 15,4 (S), 17,3 (S), 20,2 (S). TAMBIEN ESTA REFERIDA LAS FORMAS CRISTALINAS (II), (III) Y (IV) DE LA SAL TOSILATO DE (5S,8S)-8-[{(1R)-1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-DIAZASPIRO[4.5]DECAN-2-ONA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78928006P | 2006-04-05 | 2006-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20142329A1 true PE20142329A1 (es) | 2015-01-30 |
Family
ID=38542035
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014000758A PE20142329A1 (es) | 2006-04-05 | 2007-04-04 | Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona |
PE2007000413A PE20071220A1 (es) | 2006-04-05 | 2007-04-04 | Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona y su proceso de preparacion |
PE2011001795A PE20120545A1 (es) | 2006-04-05 | 2007-04-04 | Composicion farmaceutica que comprende la forma i cristalina de la sal clorhidrato monohidrato de (5s,8s)-8-[{(1r)-1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4,5]decan-2-ona |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007000413A PE20071220A1 (es) | 2006-04-05 | 2007-04-04 | Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona y su proceso de preparacion |
PE2011001795A PE20120545A1 (es) | 2006-04-05 | 2007-04-04 | Composicion farmaceutica que comprende la forma i cristalina de la sal clorhidrato monohidrato de (5s,8s)-8-[{(1r)-1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4,5]decan-2-ona |
Country Status (16)
Country | Link |
---|---|
US (5) | US8178550B2 (es) |
EP (4) | EP2004646B1 (es) |
JP (3) | JP5352446B2 (es) |
CN (2) | CN101437821B (es) |
AR (1) | AR060353A1 (es) |
CA (1) | CA2648604C (es) |
ES (1) | ES2584838T3 (es) |
HU (2) | HUE028908T2 (es) |
LT (1) | LTPA2017031I1 (es) |
MX (1) | MX2008012935A (es) |
PE (3) | PE20142329A1 (es) |
PL (1) | PL2004646T3 (es) |
PT (1) | PT2004646T (es) |
SG (2) | SG170838A1 (es) |
TW (1) | TWI363058B (es) |
WO (1) | WO2007117486A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
PT2004646T (pt) * | 2006-04-05 | 2016-07-14 | Opko Health Inc | Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação |
EP2004148B1 (en) | 2006-04-05 | 2015-07-15 | OPKO Health, Inc. | Pharmaceutical formulations comprising salts of (5S,8S)-8-[{(1 R)-1-(3,5-Bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1 ,7-diazaspiro[4.5]decan-2-one and their medical use |
PE20081891A1 (es) | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
AR066191A1 (es) * | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
CN104496988B (zh) * | 2008-09-05 | 2017-04-12 | 欧科生医股份有限公司 | 用于合成8‑[{1‑(3,5‑双‑(三氟甲基)苯基)‑乙氧基}‑甲基]‑8‑苯基‑1,7‑二氮杂‑螺[4.5]癸‑2‑酮化合物的方法和中间体 |
EP2464230B1 (en) * | 2009-08-14 | 2016-10-05 | OPKO Health, Inc. | Intravenous formulations of rolapitant |
CN105017251B (zh) * | 2015-06-30 | 2018-06-29 | 齐鲁制药有限公司 | 一种nk-1受体拮抗剂的制备方法及其中间体 |
FR3047665B1 (fr) | 2016-02-17 | 2020-12-11 | Pf Medicament | Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees |
CN106866669A (zh) * | 2017-04-19 | 2017-06-20 | 成都百特万合医药科技有限公司 | 一种合成罗拉吡坦中间体的方法 |
CN114144416A (zh) * | 2019-07-25 | 2022-03-04 | 英特维特国际股份有限公司 | Telmapitant或(5R,8S)-8-[[(1R)-1-[3,5-双(三氟甲基)苯基]乙氧基]甲基]-8-苯基-1,3,7-三氮杂螺[4.5]癸烷-2,4-二酮的晶型 |
US20230190740A1 (en) | 2020-04-03 | 2023-06-22 | Nerre Therapeutics Limited | An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods) |
AU2021285503A1 (en) | 2020-06-02 | 2022-12-08 | Nerre Therapeutics Limited | Neurokinin (NK)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2141174T3 (es) | 1992-10-28 | 2000-03-16 | Merck Sharp & Dohme | 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina. |
CA2150951A1 (en) | 1992-12-14 | 1994-06-23 | Angus Murray Macleod | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
EP0739336B1 (en) | 1994-01-13 | 1998-08-26 | MERCK SHARP & DOHME LTD. | Gem-disubstituted azacyclic tachykinin antagonists |
EP0858341B1 (en) | 1995-08-28 | 2001-10-24 | Schering Corporation | Combination therapy for advanced cancer comprising temozolomide and cisplatin |
US5939098A (en) | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
TR199903299T2 (xx) | 1997-07-02 | 2000-07-21 | Merck & Co., Inc. | Ta�ikinin resept�r antagonisti 2-(R)-(1-(R)- (3,5-Bis(triflorometil) Fenil)Etoksi-3-(S)- (4-Floro)Fenil-4- (3-5(-okso-1H,4H-1,2,4-Triazolo) metilmorfolin'in polimorfik formu. |
CA2437402A1 (en) | 2001-02-12 | 2002-08-22 | Teva Pharmaceutical Industries, Ltd. | New crystal forms of oxcarbazepine and processes for their preparation |
PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
EP1575962A1 (en) | 2002-12-24 | 2005-09-21 | Teva Pharmaceutical Industries Limited | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
GB0321256D0 (en) | 2003-09-11 | 2003-10-08 | Generics Uk Ltd | Novel crystalline compounds |
AU2004308935A1 (en) * | 2003-12-22 | 2005-07-14 | Schering Corporation | Pharmaceutical compositions |
US7498438B2 (en) | 2004-04-07 | 2009-03-03 | Schering Corporation | Fused ring NK1 antagonists |
SG187416A1 (en) | 2004-07-01 | 2013-02-28 | Opko Health Inc | Piperidine derivatives as nk1 antagonists |
JP2008519584A (ja) | 2004-11-09 | 2008-06-12 | シェーリング コーポレイション | 患者のmgmtレベルに基づいて癌を処置するための、テモゾロミドの改良された投薬養生法 |
EP2004148B1 (en) * | 2006-04-05 | 2015-07-15 | OPKO Health, Inc. | Pharmaceutical formulations comprising salts of (5S,8S)-8-[{(1 R)-1-(3,5-Bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1 ,7-diazaspiro[4.5]decan-2-one and their medical use |
PT2004646T (pt) | 2006-04-05 | 2016-07-14 | Opko Health Inc | Sais cloridrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)- etoxi} -metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona e processo para a sua preparação |
CL2007000947A1 (es) | 2006-04-05 | 2008-01-25 | Schering Corp | Formas cristalinas de las sales de esilato, oxalato, mesilato y maleato de 8-[[1-(3,5-bis-(trifluorometil)fenil)-etoxi]-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; composicion farmaceutica; y uso en la preparacion de un medicamento par el tratamiento y/o prevencion de emesis y/o nausea. |
ES2652670T3 (es) | 2006-08-07 | 2018-02-05 | Palau Pharma, S.A. | Compuestos antifúngicos cristalinos |
PE20081891A1 (es) | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
AR066191A1 (es) * | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
CN104496988B (zh) | 2008-09-05 | 2017-04-12 | 欧科生医股份有限公司 | 用于合成8‑[{1‑(3,5‑双‑(三氟甲基)苯基)‑乙氧基}‑甲基]‑8‑苯基‑1,7‑二氮杂‑螺[4.5]癸‑2‑酮化合物的方法和中间体 |
EP2464230B1 (en) * | 2009-08-14 | 2016-10-05 | OPKO Health, Inc. | Intravenous formulations of rolapitant |
-
2007
- 2007-04-04 PT PT77746402T patent/PT2004646T/pt unknown
- 2007-04-04 JP JP2009504269A patent/JP5352446B2/ja not_active Expired - Fee Related
- 2007-04-04 PE PE2014000758A patent/PE20142329A1/es not_active Application Discontinuation
- 2007-04-04 PE PE2007000413A patent/PE20071220A1/es active IP Right Grant
- 2007-04-04 TW TW096112166A patent/TWI363058B/zh not_active IP Right Cessation
- 2007-04-04 PE PE2011001795A patent/PE20120545A1/es active IP Right Grant
- 2007-04-04 MX MX2008012935A patent/MX2008012935A/es active IP Right Grant
- 2007-04-04 US US11/732,548 patent/US8178550B2/en active Active
- 2007-04-04 AR ARP070101438A patent/AR060353A1/es not_active Application Discontinuation
- 2007-04-04 CN CN200780015817.4A patent/CN101437821B/zh not_active Expired - Fee Related
- 2007-04-04 SG SG201102463-5A patent/SG170838A1/en unknown
- 2007-04-04 EP EP07774640.2A patent/EP2004646B1/en not_active Revoked
- 2007-04-04 CA CA2648604A patent/CA2648604C/en active Active
- 2007-04-04 EP EP13179415.8A patent/EP2662374A1/en not_active Withdrawn
- 2007-04-04 PL PL07774640.2T patent/PL2004646T3/pl unknown
- 2007-04-04 ES ES07774640.2T patent/ES2584838T3/es active Active
- 2007-04-04 HU HUE07774640A patent/HUE028908T2/en unknown
- 2007-04-04 EP EP13179424.0A patent/EP2676957A1/en not_active Withdrawn
- 2007-04-04 EP EP13179376.2A patent/EP2662373A1/en not_active Withdrawn
- 2007-04-04 CN CN2011101619320A patent/CN102276606B/zh not_active Expired - Fee Related
- 2007-04-04 WO PCT/US2007/008344 patent/WO2007117486A2/en active Application Filing
- 2007-04-04 SG SG10201500027TA patent/SG10201500027TA/en unknown
-
2009
- 2009-11-06 US US12/614,108 patent/US8470842B2/en active Active
-
2012
- 2012-11-19 JP JP2012253653A patent/JP5856944B2/ja not_active Expired - Fee Related
-
2013
- 2013-06-21 US US13/923,859 patent/US20130281477A1/en not_active Abandoned
-
2014
- 2014-09-25 JP JP2014194788A patent/JP6122411B2/ja active Active
-
2015
- 2015-04-10 US US14/683,871 patent/US10196394B2/en active Active
-
2017
- 2017-10-16 LT LTPA2017031C patent/LTPA2017031I1/lt unknown
- 2017-10-16 HU HUS1700037C patent/HUS1700037I1/hu unknown
-
2019
- 2019-01-09 US US16/243,404 patent/US20190375751A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20142329A1 (es) | Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona | |
PE20120083A1 (es) | Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a | |
CR10088A (es) | Compuestos de piperazina con accion herbicida | |
UY30327A1 (es) | Nuevos compuestos ii | |
DE602005000208D1 (de) | Kraftstoffzufuhrsystem | |
ECSP088594A (es) | Compuestos de piperazina con efecto herbicida | |
DOP2010000047A (es) | Compuestos de pirazol y su uso como inhibidores de raf | |
RS53574B1 (en) | PYROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | |
NI200900032A (es) | Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3 | |
DK3106463T6 (da) | Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer | |
UY31468A1 (es) | Derivados bis-(sulfonilamino) en terapia 065 | |
BR112013025881A2 (pt) | composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii) | |
ECSP099571A (es) | Derivados pirazólicos como inhibidores de la 11-beta-hsd1 | |
RS53003B (en) | C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS | |
ECSP099565A (es) | Compuesto de 2-amino pirimidina | |
BRPI0515918A (pt) | sais de composto heterocìclico de ligação à quimiocina e métodos para seu uso | |
ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
EA200702039A1 (ru) | 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны | |
WO2011098408A3 (de) | Hydrazin-substituierte anthranilsäurederivate | |
DE502004006660D1 (de) | Verdampfungseinheit f r einen kraftstofffilter | |
UY29804A1 (es) | Quinolinas de alquilnitrilo | |
AR090209A1 (es) | Polimorfos de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea y composiciones farmaceuticas que los comprenden | |
DE602006011941D1 (de) | Speicherkraftstoffeinspritzsystem | |
DE602007003295D1 (de) | Holographisches Speichersystem mit Apodisierungsfilter | |
AR060352A1 (es) | Sales de 8- [(1- (3,5-bis- (trifluorometil) fenil) -etoxi) -metil] -8-fenil-1,7 -diaza- espiro [4.5] decan -2-ona y proceso de preparacion de las mismas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |